Annual Reporting Under an Open Investigational New Drug Application: Regulatory Operations and eCTD Submission Considerations for a Cardiac Myosin Inhibitor in Obstructive Hypertrophic Cardiomyopathy

Sponsors that hold an IND but not the underlying marketing application face a specific annual reporting problem: some sections of the eCTD annual report hierarchy belong to marketing applications and must be left empty. This article prepares the regulatory operations components of the first annual report for a hypothetical IND held by a follow-on sponsor of a cardiac myosin inhibitor, with a right of reference to an approved application for quality and nonclinical information. The IND supports a completed Phase 1 study (30 entered) and an enrolling Phase 2 study (38 of 120 planned entered). The article reconciles enrollment and demographics, reports blinded pooled adverse events, lists one outstanding item with FDA in the optional log, maps each paragraph of 21 C.F.R. 312.33 to Module 1.13 and identifies sections that do not apply, and builds a timeline to a March 23, 2027 deadline with Day 46 as the target.Keywords: IND annual report; 21 C.F.R. 312.33; eCTD Module 1.13; regulatory operations; Form FDA 1571; submission lifecycle

Authors

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-21
DOI
https://doi.org/10.5281/zenodo.24421001
Primary Topic
Healthcare Regulation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Annual Reporting Under an Open Investigational New Drug Application: Regulatory Operations and eCTD Submission Considerations for a Cardiac Myosin Inhibitor in Obstructive Hypertrophic Cardiomyopathy

Kishan Rajput, Peivand Pirouzi, Pruthvirajsinh Sindha, Sukhpreet Singh Maan et al.
Zenodo (CERN European Organization for Nuclear Research)
Healthcare Regulation
article

Annual Reporting Under an Open Investigational New Drug Application: Regulatory Operations and eCTD Submission Considerations for a Cardiac Myosin Inhibitor in Obstructive Hypertrophic Cardiomyopathy

Kishan Rajput, Peivand Pirouzi, Pruthvirajsinh Sindha, Sukhpreet Singh Maan, Vraj Modi
article en

Abstract

Sponsors that hold an IND but not the underlying marketing application face a specific annual reporting problem: some sections of the eCTD annual report hierarchy belong to marketing applications and must be left empty. This article prepares the regulatory operations components of the first annual report for a hypothetical IND held by a follow-on sponsor of a cardiac myosin inhibitor, with a right of reference to an approved application for quality and nonclinical information. The IND supports a completed Phase 1 study (30 entered) and an enrolling Phase 2 study (38 of 120 planned entered). The article reconciles enrollment and demographics, reports blinded pooled adverse events, lists one outstanding item with FDA in the optional log, maps each paragraph of 21 C.F.R. 312.33 to Module 1.13 and identifies sections that do not apply, and builds a timeline to a March 23, 2027 deadline with Day 46 as the target.Keywords: IND annual report; 21 C.F.R. 312.33; eCTD Module 1.13; regulatory operations; Form FDA 1571; submission lifecycle

Zenodo (CERN European Organization for Nuclear Research)
Northeastern University (US)
Healthcare Regulation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Annual Reporting Under an Open Investigational New Drug Application: Regulatory Operations and eCTD Submission Considerations for a Cardiac Myosin Inhibitor in Obstructive Hypertrophic Cardiomyopathy — Kishan Rajput, Peivand Pirouzi, et al. · Zenodo (CERN European Organization for Nuclear Research) (2026) | TGRS Research Map | TGRS